InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes

The largest of three phase 3 studies of the novel investigational SGLT1/SGLT2 inhibitor shows that it improves glycemic control and may reduce body weight and BP but also raises some risks, including DKA.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news